Cardiovascular risk impact of cyclosporine immunosuppression in renal transplant recipients.
Paul
L C
LC
Department of Medicine, University of Calgary, Alberta, Canada.
Sutherland
F
F
Klassen
J
J
Buckle
S
S
Burgess
E
E
D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality*; D002423:Cause of Death; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000401:mortality*; D006650:Histocompatibility Testing; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000276:immunology / Q000401:mortality*
D000959:Antihypertensive Agents; D016572:Cyclosporine; D002784:Cholesterol; D001379:Azathioprine